While CAR-T cell therapy has shown remarkable success in treating blood cancers, its application in solid tumors represents the next frontier of innovation. This category highlights the latest scientific breakthroughs, clinical trials, and technological strategies aimed at overcoming the unique challenges of solid tumor environments—such as tumor heterogeneity, immunosuppressive microenvironments, and poor T-cell infiltration. Learn how researchers and biotech companies in China are driving progress with novel CAR designs, combination therapies, and localized delivery systems. Follow the journey of CAR-T therapy as it evolves to tackle solid tumors and bring new hope to patients facing hard-to-treat cancers.
T-Maximum Pharmaceutical has announced that its investigational B7-H3-targeted CAR-T therapy, MT027, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma.
A remarkable case published in Journal of Hematology & Oncology highlights the potential of satricabtagene autoleucel (CT041), the world’s first approved solid tumor CAR-T therapy, in treating advanced gastric cancer with peritoneal metastasis. After receiving CT041 following first-line therapy, a 53-year-old patient achieved complete disappearance of peritoneal lesions, underwent successful conversion surgery, and maintained disease control for 48 months.
A phase I clinical study published in Journal of Hematology & Oncology reported long-term outcomes of three advanced gastric cancer patients with peritoneal metastasis treated with Satri-cel (Shuricabtagene Autoleucel). Patients achieved durable peritoneal disease control, with the longest follow-up reaching 48 months.
At ASCO 2026, CARsgen Therapeutics presented more than 4.5 years of follow-up data demonstrating durable responses, prolonged progression-free survival, and a favorable safety profile for Satri-cel (CT041) in advanced gastric and gastroesophageal junction cancer.
A Phase I study published in the Journal of Clinical Oncology showed promising results for GUCY2C-targeted CAR-T therapy in advanced colorectal cancer, with tumor shrinkage observed in more than half of treated patients and durable responses lasting beyond nine months.
Satri-cel injection (CT041, Kaileimei®), the world’s first CAR-T cell therapy for solid tumors, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive, HER2-negative advanced
CLDN18.2 has become one of the most promising therapeutic targets in pancreatic cancer. From bispecific antibodies and antibody-drug conjugates to CAR-T cell therapy, researchers are exploring innovative approaches that could transform treatment options for patients with this difficult-to-treat disease.
A novel nanobody-based CAR-T therapy targeting Claudin18.2 has demonstrated remarkable efficacy and safety in gastric and gastroesophageal junction cancers, achieving a 66.7% response rate and sustained complete remission beyond 60 weeks in early clinical trials.
The inclusion of satri-cel in CSCO guidelines signals a major transition of CAR-T therapy from trials to clinical practice in solid tumors.
China’s CAR-T research has entered a new era in 2026, with major breakthroughs in solid tumors such as gastric cancer, lung cancer, liver cancer, and colorectal cancer. Satri-cel, the world’s leading CLDN18.2-targeted CAR-T therapy, may become the first approved CAR-T treatment for solid tumors globally.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.